Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

J Neurooncol. 2007 Mar;82(1):81-3. doi: 10.1007/s11060-006-9241-y. Epub 2006 Aug 31.

Abstract

Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Alkylating / administration & dosage*
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / pathology
  • Brain Neoplasms / radiotherapy*
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Dacarbazine / administration & dosage
  • Dacarbazine / analogs & derivatives*
  • Female
  • Glioblastoma / drug therapy
  • Glioblastoma / pathology
  • Glioblastoma / radiotherapy*
  • Humans
  • Male
  • Middle Aged
  • Necrosis
  • Radiation-Sensitizing Agents / administration & dosage*
  • Radiotherapy Dosage
  • Temozolomide
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Alkylating
  • Radiation-Sensitizing Agents
  • Dacarbazine
  • Temozolomide